Advertisement

Organisation › Details
Kyan Technologies Pte Ltd.
KYAN Technologies, a pioneering leader in the field of functional precision medicine. Our company is dedicated to revolutionizing cancer care by leveraging cutting-edge technology and expertise. KYAN has developed Optim.AI, a state-of-the-art platform solution for clinical decision support and efficient drug development. This powerful tool empowers healthcare providers and scientists by providing them with critical insights to make informed clinical and research decisions. Our core mission is to bridge the existing gap in cancer care, and we achieve this through our unique specialization in integrating small data AI and biological experiments. Through our proprietary platform, we offer a truly personalized solution that transforms the identification of optimal outcomes from vast drug-dose combinations, to improve the development and delivery of therapies to patients. In addition to supporting healthcare providers and patients, KYAN is committed to aiding more efficient and accelerated drug development. From the development of novel biopharmaceutical assets to repurposing and expanding the use of drugs, KYAN’s aim is to help bring better treatment options to as many patients as possible. *
![]() |
Start | 2023-09-29 renamed before |
Predecessor | Kyan Therapeutics Pte Ltd. | |
![]() |
Industry | Optim.AI™ technology platform |
Industry 2 | artificial intelligence (AI) / machine learning (ML) | |
![]() |
Person | Saavedra, Hugo (Kyan Therapeutics 202304 CEO) |
Street | 1 Research Link #05-45 | |
City | 117604 Singapore | |
Tel | +65-6974-0426 | |
Address record changed: 2023-09-30 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: CellPhenomics GmbH. (9/29/23). "Press Release: Kyan Technologies, Alentis Therapeutics, and CellPhenomics Join Forces Combining Cutting-edge Optim.AI and PD3D Models to Advance Claudin-1 Expression Research". Singapore, Berlin & Allschwil. | ||
Record changed: 2024-09-22 |
Advertisement

More documents for Kyan Technologies Pte Ltd.
- [1] CellPhenomics GmbH. (9/29/23). "Press Release: Kyan Technologies, Alentis Therapeutics, and CellPhenomics Join Forces Combining Cutting-edge Optim.AI and PD3D Models to Advance Claudin-1 Expression Research". Singapore, Berlin & Allschwil....
- [2] CellPhenomics GmbH. (4/14/23). "Press Release: CELLphenomics’ and Kyan Therapeutics Combined Platforms Provide Best-in-Class Solutions to Support the Biopharma Industry". Berlin & Singapore....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top